Navigation Links
Continuous oral contraceptives better at easing pain, bleeding
Date:4/3/2008

Continuous oral contraceptives may be more effective than the standard 28-day birth control pills in suppressing the ovary, according to researchers. They say that the continuous pill also causes a significant improvement in pain and behavioral changes.

"We have provided a biological proof of concept that both the ovary and the lining of the uterus are suppressed better and quicker with the continuous pill than with the cyclic pill. And there is no harmful effect on the lining of the uterus either," said Richard Legro, M.D., professor of obstetrics and gynecology, Penn State College of Medicine and lead author of the study.

Standard 28-day birth control pills mimic a woman's natural menstrual cycle, while preventing pregnancy. A standard dose includes 21 hormone pills to suppress growth in the endometrium, the lining of the uterus, and seven placeholder placebo pills.

Continuous oral contraceptives may be more effective in treating several medical conditions, where continuous ovarian suppression is desired, such as acne, hirsutism, premenstrual syndrome, endometriosis and polycystic ovary syndrome. But there have been few detailed studies of ovarian function on the pill to demonstrate this effect.

Legro and his colleagues compared the effectiveness of continuous oral contraceptives with that of the cyclical pills. The researchers monitored 62 healthy women, randomly assigned to receive either cyclical or continuous birth control pills, for six months with both researchers and participants blinded to the study group.

"We monitored vaginal bleeding, quality of life, and ovarian and endometrial suppression," said Legro, whose team's findings appeared in a recent issue of the Journal of Clinical Endocrinology and Metabolism.

The researchers found a significant decrease in moderate to heavy bleeding days among women who received the continuous birth control regimen. Women in the continuous group also had a significant decline in circulating and urinary estrogen levels, total ovarian volume and lead follicle size all biomarkers that indicate the ovary is less active and reported less pain and behavioral changes compared to women in the cyclic group.

However, results from the study also indicate greater breakthrough bleeding, or spotting, among women in the continuous group. Legro says that while greater breakthrough bleeding may be a truly objectionable side effect for many women, it does not seem to affect their quality of life.

"That is one of the unique things of this study. The quality of life did not necessarily decrease as it was counterbalanced by improvements in other areas such as pain and mood swings," the Penn State researcher added.

According to Legro, the study suggests that there may be diverse mechanisms of breakthrough bleeding depending on whether a woman is using either a cyclical or continuous regimen of birth control pills.

In the case of cyclic pills, the ovary comes back into the equation during the pill free interval leading to a rebound increased secretion of ovarian hormones, which in turn contributes to some breakthrough bleeding, he explained.

"Breakthrough bleeding in the continuous group, in our opinion, is most likely due to the fact that the pill does too good of a job in suppressing the ovary and the lining of the uterus gets a little bit thin and fragile so that from time to time there is a little bit of bleeding," added Legro, whose work is funded by the National Institutes of Health.

The study provides a physical reason for continuous oral contraceptive pills to treat such chronic medical conditions such as polycystic ovary syndrome, endometriosis and premenstrual syndrome, where additional suppression of the ovary or the endometrium is desired, and Legro noted that other chronic conditions such as hypertension or diabetes are treated continuously, not three weeks out of four. Further studies showing a favorable risk benefit ratio of continuous oral contraceptives on these disorders are the next step.


'/>"/>

Contact: Amitabh Avasthi
axa47@psu.edu
814-865-9481
Penn State
Source:Eurekalert

Related biology news :

1. Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time & Attendance Solutions
2. Texas A&M testing oral contraceptives for animals
3. David H. Ledbetter, PhD, FACMG is the 2008-2009 Luminex/ACMGF Award recipient
4. Ant guts could pave the way for better drugs
5. Newly defined signaling pathway could mean better biofuel sources
6. Analysis calls for medical device information to better serve patients and doctors
7. Better protection for biomedial devices could result from Rutgers-Camden research
8. Researchers develop better membranes for water treatment, drug delivery
9. Marine scientists warn human safety, prosperity depend on better ocean observing system
10. Human safety, prosperity depend on better ocean observing system: Scientists
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: